Division of Genetic Medicine and Clinical Pharmacology

The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.

The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.

Jackson Roberts II, MD, an internationally known clinical pharmacologist in the Vanderbilt University School of Medicine who helped define the role of lipid peroxidation and oxidative stress in human disease, died May 31 in Nashville. He was 79.

Vanderbilt University Medical Center's Lea Davis, PhD, and longtime colleagues Ekaterina (Katya) Khramtsova, PhD, and Barbara Stranger, PhD, are among seven authors of a paper published May 11 in the journal Cell that outlines “best practices” for evaluating the impact of both sex and gender on human health.

A transcontinental research effort led by scientists from Vanderbilt University Medical Center and the University of Michigan has upended some long-standing assumptions about mutations — how often they occur, what causes them and what they do.

A machine learning method based on neural networks outperformed a mutational scanning model at identifying disease-causing mutations in an Alzheimer’s disease protein, suggesting the method could be useful for facilitating therapeutic design.

Polygenic risk scores — scores that reflect the influence of common genetic variants — could be used to predict the likelihood of developing chronic overlapping pain conditions and guide biomarker and targeted prevention efforts.